H.R.5740 - To provide for the mandatory recall of adulterated or misbranded drugs.111th Congress (2009-2010)
|Sponsor:||Rep. Towns, Edolphus [D-NY-10] (Introduced 07/14/2010)|
|Committees:||House - Energy and Commerce|
|Latest Action:||House - 07/14/2010 Referred to the House Committee on Energy and Commerce. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.5740 — 111th Congress (2009-2010)All Information (Except Text)
Introduced in House (07/14/2010)
Amends the Federal Food, Drug, and Cosmetic Act to require any registered producer of a drug or device to notify the Secretary of Health and Human Services (HHS), as soon as practicable, of the identity and location of a drug, if such person has reason to believe: (1) that such drug is adulterated or misbranded; and (2) there is a reasonable probability that the use or consumption of, or exposure to, the drug will cause a threat of serious adverse health consequences or death to humans or animals.
Authorizes the Secretary to: (1) request that any person who distributes a drug that the Secretary has reason to believe is adulterated, misbranded, or otherwise in violation of the FFDCA voluntarily recall such drug; (2) issue an order requiring any person who distributes a drug that may cause serious adverse health consequences or death to humans or animals to immediately cease distribution of such drug; (3) amend the order to cease distribution to include a recall of the drug after an opportunity for an informal hearing; and (4) issue an order requiring an immediate recall of a drug if the Secretary has credible evidence or information that a drug subject to a cease distribution or recall order presents an imminent threat of serious adverse health consequences or death to humans or animals. Provides for notice to affected persons.
Prohibits the failure to comply with the notification requirements of, or orders issued pursuant to, this Act.
Requires the Secretary to provide notice of a recall order to consumers to whom the drug was, or may have been, distributed and to appropriate state and local health officials, as necessary.